herb · for slow recovery
Echinacea
Stirs up immune cells so an infection clears sooner.
Say that in clinical terms
Stimulates immune cell proliferation and reduces infection duration through enhanced pathogen clearance.
How strong is the research?
A Cochrane review of 24 trials in 4,631 people found it does not clearly help treat a cold.
3 papers read, 2 supporting, 1 against.
Tested as: Echinacea purpurea ethanolic extract (based on the 2015 meta-analysis subgroup finding)
Who was studied: Adults with a cold, in treatment trials.
How much to take
three times daily
300–500 mg
Begin at first symptoms. May reduce cold duration by 1-2 days.
Before you take it
- No NIH/IOM Tolerable Upper Intake Level (UL) established for Echinacea — it is an herbal preparation without a defined dietary UL; NCCIH rates it 'likely safe' for most adults for short-term use (weeks to a few months).
- Potential interaction with immunosuppressant drugs (e.g., cyclosporine, tacrolimus): theoretical basis is immune stimulation reducing drug efficacy; however, lipophilic (alkamide-containing) echinacea preparations may actually suppress cellular immunity, making this interaction preparation-dependent and debated in the literature.
- Traditional contraindication in autoimmune conditions (lupus, MS, rheumatoid arthritis) is increasingly questioned: lipophilic preparations have shown suppression of cellular immune responses in some studies, and beneficial effects in autoimmunity have been reported; contraindication remains precautionary rather than firmly established.
- Allergic reactions possible in individuals sensitive to the Asteraceae/Compositae plant family (ragweed, chrysanthemum, marigold, daisy); severity can range from mild skin reactions to anaphylaxis.
- Pregnancy: at least one prospective cohort study found E. purpurea extracts non-teratogenic in first trimester; NCCIH rates short-term use 'possibly safe'; long-term pregnancy data absent; some commercial preparations have been found to contain heavy metal contaminants (e.g., lead), which represents a separate preparation-specific risk during pregnancy.
- Possible modulation of CYP1A2 and CYP3A4 hepatic enzymes — clinical significance unclear; caution warranted when co-administered with narrow-therapeutic-index medications metabolized by these pathways.
- Common adverse effects are mild and reversible: gastrointestinal upset, nausea, unpleasant taste.
- Product heterogeneity is a fundamental safety consideration: E. purpurea, E. pallida, and E. angustifolia differ chemically; root vs. aerial parts differ substantially; extraction method (pressed juice, ethanolic extract, dried herb) alters the chemical profile; safety and efficacy evidence from one preparation does not automatically transfer to another.
What we make of it
The Cochrane review states it has not been shown to help treat colds.
The detail
The 2014 Cochrane review concluded explicitly that echinacea products have not been shown to provide benefit for treating a cold — which is the outcome this claim is about.